Lexicon (LXRX) Trading Overview
- Price Movement (24‑hour period ending 10:49 PM CET, Friday 23 Feb 2026): –4.49 %.
- Current Share Price: USD 1.42 (traded on major exchanges).
- Shares Outstanding: 445 million.
- Market Capitalisation: USD 694.1 million.
- Volume (last 24 hours): USD 2 million worth of shares exchanged.
- Month‑to‑Month Performance: –27.67 % since the end of the previous month.
- 200‑Day Simple Moving Average: USD 1.88.
- 52‑Week High: USD 2.68 (30 June 2026).
- 52‑Week Low: USD 1.10 (30 January 2026).
Comparative Performance of Related Stocks
| Ticker | 24‑hour Change | Current Price | Market Capitalisation (USD mn) | P/E Ratio |
|---|---|---|---|---|
| SPFI (South Plains) | –0.87 % | USD 43.02 | 817.6 | 11.82 |
| MITK (Mitek) | –1.49 % | USD 18.64 | 818.1 | 38.88 |
| 0ET.F (Esperion Therapeutics) | –0.31 % | USD 3.18 | 819.5 | – |
| AHCO (Adapthealth) | 0 % | USD 6.02 | 831.7 | – |
| ABUS (Arbutus Biopharma) | +0.72 % | USD 4.20 | 828.1 | 5.34 |
South Plains (SPFI)
- Q3 2026 Results (reported 22 Oct 2026): Net income and earnings per share increased relative to the prior quarter. Net‑interest margin and cost of deposits remained stable. Loan portfolio grew, partly due to an acquisition; deposit balances increased modestly.
- Dividend: Quarterly cash dividend declared; payment scheduled for mid‑November.
- Post‑Earnings Conference Call: Held on 22 Oct 2026; recordings available on the company’s website.
Mitek (MITK)
- No additional corporate updates were disclosed for the period under review.
Esperion Therapeutics (0ET.F)
- No further corporate updates were disclosed for the period under review.
Adapthealth (AHCO)
- No further corporate updates were disclosed for the period under review.
Arbutus Biopharma (ABUS)
- Recent Filing (20 Oct 2026): FDA removed the clinical hold on the investigational new drug application for AB‑101, an oral PD‑L1 inhibitor.
- Clinical Status: AB‑101 completed a Phase 1a/1b trial demonstrating tolerability, high receptor occupancy in patients with chronic hepatitis B, and preliminary evidence of viral antigen decline in a subset of subjects.
- Future Plans: The company may continue additional development of AB‑101 in the United States and is evaluating next steps.
- Financial Statements: Standard financial statements and exhibits are included; no new financial results are reported.
About Lexicon (LXRX)
Lexicon Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in The Woodlands, United States. The company conducts research and development of treatments for a range of conditions including diabetes, obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. Lexicon is listed on the Nasdaq stock exchange and can be accessed via its website at www.lexpharma.com . The company’s initial public offering was conducted on 7 April 2000.
